INTRODUCTION
Due to the extreme difficulties to cure distant metastasis, colorectal cancer (CRC) is the second leading cause of cancer death in Western countries (Jemal et al., 2011) . The complex mechanisms leading to cancer metastasis are far from being completely understood, and it is still unclear which cell subset is able to migrate, survive, and grow at the metastatic site (Chaffer and Weinberg, 2011) .
In recent years, a growing body of evidence has provided support for the existence of cellular hierarchies within many tumor types where cancer stem cells (CSCs), commonly identified by their cell-surface-marker expression, are the unique source of all tumor cells and responsible for tumor propagation and relapse (Valent et al., 2012) . CSCs, defined by their capacity for self-renewal and resistance to conventional chemotherapies, are believed to remain after cancer therapy to initiate the metastatic process (Brabletz et al., 2005) , and their ability to do so has been reported for several forms of cancers. Human pancreatic CSCs expressing the putative stem cell marker CD133 and the chemokine receptor CXCR4 lost their metastatic activity when the CXCR4 + population was depleted, suggesting that
CSCs may hijack cytokine-regulated migration-signaling pathways to initiate metastasis (Hermann et al., 2007) . In breast cancer, ectopic expression of Twist and Snail, two transcription factors directly involved in epithelial mesenchymal transition (EMT) and metastasis development, lead to increased expression of stem cells markers and enhanced tumorigenesis, indicating that a tight connection between EMT activation and CSC phenotype drives the metastatic process (Mani et al., 2008) . More recently, a CD26 + CSC population present in both primary colorectal tumors and liver metastasis was demonstrated to give rise to metastatic lesions in the liver when orthotopically injected in immunocompromised mice (Pang et al., 2010) . These studies provide a few examples of cancers where CSCs isolated from both primary and metastatic tumors were demonstrated to have the capacity to initiate metastasis. However, whether the cell-surface markers that identify CSCs play a functional role in the molecular events within the tumor environment that drive tumorigenesis and result in the cancer spreading to other organs has been difficult to pinpoint for most CSC populations identified to date. This is an important goal for the field, because understanding whether the cell-surface phenotype of CSC is mechanistically linked with the metastatic process may help develop effective therapeutic agents targeting CSCs. CD44 is a widely expressed polymorphic integral membrane adhesion molecule that binds hyaluronic acid and contributes to cell-cell and cell-matrix adhesion, cell growth and trafficking, EMT, and tumor progression (Orian-Rousseau, 2010) . The vast majority of tumors express CD44, whose detection in combination with other antigens is able to enrich for CSCs in several different tumor types ( Data are mean ± SD of four independent sets from different donors of six tumors per group. Right, hematoxylin and eosin (H&E) staining of mouse caecum bearing primary tumors generated by injection of CD44v6 + and CD44v6 À cells. The scale bars represent 150 mm.
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CD44v6 in Metastatic Colon Cancer Stem Cells et al., 2008) . CD44 transcripts undergo complex alternative splicing, resulting in functionally different isoforms expressed primarily on epithelial cells (Tö lg et al., 1993) . Although the expression of standard isoform (CD44s) has been more extensively studied, the variant isoforms (CD44v) seem restricted to subpopulations endowed with stem cell potential and cancer development. This seems to be particularly true in the gut. Although intestinal stem cells express both standard and variant CD44 isoforms, CD44v, but not CD44s, isoforms promote the generation of gut adenoma in mouse models of familial adenomatous polyposis (Zeilstra et al., 2014) . Among CD44v isoforms, CD44v6 seems to play a major role in cancer progression for its ability to bind hepatocyte growth factor (HGF), osteopontin (OPN), and other major cytokines produced by tumor microenvironment (Orian-Rousseau, 2010). The major role of CD44v6 involves cell migration and invasion. CD44v6 interacts with hepatocyte growth factor receptor (MET) in the presence of HGF and potentiates its signaling (Orian-Rousseau et al., 2002) . CD44v expression is downstream of the Wnt signaling and induced by the b-catenin/Tcf-4 signaling pathway (Wielenga et al., 2000) . Nuclear b-catenin accumulates in the undifferentiated CRC cells at the invasive front, whereas a gradual loss is detected in the well-differentiated tumor areas, suggesting its role as marker predictor for cancer metastasis (Brabletz et al., 2005) . The interaction between tumor and its microenvironment is critical for cancer progression, which is promoted by different cytokines produced by stroma or accessory cells present in proximity to the tumor lesion (Whiteside, 2008) . OPN is a cytokine produced by fibroblasts and immune and endothelial cells that is involved in several biological processes during bone turnover, tumorigenesis (Rangaswami et al., 2006) , inflammation, and immune response (Cantor and Shinohara, 2009 ). In CRC, elevated CXCR4 expression correlated with advanced tumor stages III/IV and may help identify patients with higher probability to metastasize to the liver (Schimanski et al., 2005) . Likewise, the functional expression of MET and HGF has been shown to provide a selective growth advantage to neoplastic cells at different stages of tumor progression (Di Renzo et al., 1995) .
Here, we investigated whether mechanisms regulating CD44 isoforms during developmental process would be mirrored by colorectal (CR)-CSCs during tumorigenesis and metastatic spread. We show that CR-CSCs are included in the CD44v6 + population and that such CD44v6 expression confers metastatic potential to all CR-CSCs. Engagement of MET and its coreceptor CD44v6 in CR-CSCs activates an EMT program that promotes cell motility, invasiveness, and metastasis. Furthermore, we demonstrated that HGF, OPN, and stromal-derived factor 1a (SDF-1) induce CD44v6 expression in CRC progenitor cells, which increase the tumorigenic activity while acquiring the ability to produce metastasis. Our data indicate CD44v6 as a molecule that could be clinically exploited both as a biomarker and therapeutic target in CRC.
RESULTS

CD44v6 Expression Demarcates a Highly Tumorigenic CR-CSC Population with Metastatic Potential
We and others previously demonstrated that CR-CSCs are enriched in tumor spheres or freshly isolated CD133 + cells (O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Todaro et al., 2007) . Given that CD44 has been reported as a CR-CSC marker (Dalerba et al., 2007) , we set out to investigate whether expression of CD44 variants might stratify CR-CSCs into subpopulations with distinct functional properties. Although several of the variable CD44 exons were uniformly translated across patientderived CRC subsets, mRNA levels of CD44v5 and CD44v6 appeared considerably higher in sphere-propagated CSCs and in freshly purified CD133 + cells relative to sphere-derived differentiated progeny and bulk primary cells ( Figure S1A available online). Analysis of CD44v5 mRNA in CD44v6 + cells purified from patient tumors or spheres further suggested that CD44v5 and CD44v6 are translated in the same subset of CRC cells (Figure S1B) . Interestingly, CD44v6 is significantly higher expressed in metastatic lesions than in their corresponding primary tumors ( Figure 1A ). In contrast, we found that CD44 + -expressing cells were equally present across CRC sphere cells and differentiated progeny and in primary and metastatic tumors ( Figure S1C ). Although MET, which is known to interact with CD44v6, was prominently expressed in both primary and metastatic CRCs ( Figure S1D) 
(legend continued on next page)
Cell Stem Cell Figure S2D ). CD26 has been reported as a marker of invasive and metastatic CR-CSCs (Pang et al., 2010) . Although more than 50% of the CD44v6 Figure 2I ). Interestingly, SDF-1 blockage also abrogated the upregulation of CD44v6 induced by HGF and OPN ( Figure S3H ). Because both HGF and OPN are known to upregulate CXCR4 and SDF-1, it is likely that both HGF and OPN act via the CXCR4/SDF-1 axis in CD44v6 À cells.
Cancer-Associated Fibroblasts Promote the Tumorigenic and Metastatic Activity of CRC Stem and Progenitor Cells
Cancer-associated fibroblasts (CAFs) are key players in the tumor microenvironment known to secrete compounds that potentiate tumor malignancy (Hanahan and Coussens, 2012 ure S4E ), suggesting that these compounds are secreted by CAFs during CRC tumorigenesis. Accordingly, primary cultured CAFs and freshly isolated CD90 + cells from tumor specimens produced significantly higher levels of HGF, OPN, SDF-1, and (E) In vivo imaging analysis of tumor and metastasis growth at the indicated time points. Xenografts were generated using CD44v6 
CD44v6 and MET Are Required for CRC Metastasis
To confirm that CD44v6 is required for migration of tumorigenic cells, we compared the inhibitory effect of CD44v6, HGF, or MET targeting on CR-CSCs. Transduction of spheres with lentiviral vectors encoding for specific CD44v6 and MET small hairpin RNA (shRNA) sequences significantly reduced their mRNA and protein levels, respectively ( Figures S5A, S5B , and S5C), while abolishing cell migration ( Figure 4A) . A similar inhibitory effect was obtained using a blocking CD44v6 antibody or shCD44v6, whereas HGF neutralization was slightly less effective ( Figure 4A Figures 4E and S5G ). Of note, exposure to neutralizing antibody against CD44v6 was able to prevent tumor spreading sustained by freshly isolated cells without affecting the orthotopic engraftment ( Figure 4F ), indicating that CD44v6 may act as a functional marker of cells with metastatic potential in CRC. Because CD44v6 and CD44v5 are coexpressed ( Figures  4G, S1A , and S1B), we evaluate the involvement of CD44v5 in the metastatic activity of CR-CSCs. Exogenous expression of CD44v5 in CD44v5 À /CD44v6 À CRC sphere cells promoted the expression of CD44v6 ( Figures S5H and S5I) , allowing the cells to become metastatic in the spleen-liver assay ( Figure 4H ). Altogether, these results suggest that CD44v6 could be a promising therapeutic target to prevent metastasis formation in CRC.
Wnt and BMP Pathways Control CD44v6 Expression and CSC Activity
The activation of the Wnt/b-catenin pathway is the hallmark of CR-CSCs. CD133 + CRC cells expanded in culture as tumor spheres contain a subset of tumorigenic cells with constitutively high Wnt signaling, which can be detected by a b-catenin/GFP reporter (Vermeulen et al., 2010) . By flow cytometry analysis, we also found that the vast majority of CD44v6 + cells in CRC spheres display high b-catenin activity ( Figure 5A ), in line with the high tumorigenic activity of these cells. Interestingly, immunofluorescence analysis of tumor sections indicated that CD44v6 + cells at the invasion front of aggressive tumors largely express nuclear b-catenin ( Figure 5B ). Of note, Wnt3a was able to increase expression levels of CD44v6 and clonogenic and migration activity of CRC stem and progenitor cells ( Figures  5C-5E) . Moreover, the analysis of CD44v6 À transduced with CD44v5 showed that the acquisition of CD44v6 paralleled the activation of b-catenin ( Figure 5F ), confirming the prominent role of the Wnt signaling pathway in this system. In accordance with the functional differences observed in CD44v6 + and CD44v6 À cells, cytokines able to upregulate CD44v6 promoted the expression of Wnt-, EMT-, and metastasis-related genes ( Figure 5G ). Each of these cytokines was able to activate the b-catenin pathway in CRC spheres ( Figure 5H ), in line with their ability to promote a prometastatic phenotype in CD44v6 À CRC sphere cells. Bone morphogenetic protein 4 (BMP4) and BMP2 are produced by differentiated CRC cells and are absent in cancer stem and progenitor cells (Hardwick et al., 2004; Lombardo et al., 2011) . Because BMP4 promotes the differentiation of CR-CSCs and antagonizes the Wnt pathway, we hypothesized that BMPs could repress the expression of CD44v6. CD44v6 + cells gradually decreased their b-catenin activity in presence of BMP4 ( Figure 5I ). Cytokine-and CAF-CM-induced CD44v6 expression was significantly reduced in CRC spheres treated with BMP2 or BMP4 ( Figure 5J ), suggesting that the absence of differentiating agents allows HGF, OPN, and SDF-1 to promote the expression of CD44v6 in undifferentiated CRC cells. Thus, the ability of BMPs to promote the differentiation and loss of tumorigenic activity of CR-CSCs is paralleled by the repression of CD44v6 expression promoted by Wnt pathway.
PI3K Inhibition Reduces CD44v6 Expression and Metastasis Formation in CRC
To investigate the signaling pathways involved in the metastatic behavior of CR-CSCs, we analyzed the posttranslational modifications of the proteins commonly related to the metastatic signaling pathways. Immunoblot analysis revealed a significant downregulation of PTEN and a considerable upregulation of phosphatidylinositol 3-kinase (PI3K) and activation of AKT in CRC sphere cells treated with HGF, OPN, and SDF-1, whereas a constitutive activation of the PI3K/AKT pathway was observed in CD44v6 + cells ( Figures 6A, 6B , and S6A 
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CD44v6 in Metastatic Colon Cancer Stem Cells Figures 6C and S6C ). Of note, CD44v6 + cells were the major subset dying in vitro after PI3K inhibition ( Figure 6D) . Moreover, the analysis of early signaling showed that BMP4 upregulated the expression of PTEN and impaired the activation of the PI3K/AKT pathway promoted by HGF, OPN, and SDF-1 ( Figures  6E and S6D ). To investigate whether the dependence of CD44v6 + cells to the PI3K/AKT pathway may be exploited to prevent or reduce metastasis formation in CRC, we determined the effect of treatment with the PI3K inhibitor BKM120 on the orthotopic preclinical model. Such treatment considerably reduced the metastatic spreading of CRC cells, regardless of the presence of PI3K-activating mutations ( Figures 6F and S6E) . Accordingly, exogenous expression of PI3K re-established the expression of CD44v6 and the in vivo migration of CD44v6 À cells ( Figures S6F-S6H ), confirming that the PI3K pathway plays a major role in promoting the metastatic activity of CRC cells.
CD44v6 Expression Is a Biomarker for the Clinical Outcome of CRC Patients
We next explored the clinical relevance of CD44v6 as a prognostic biomarker. In line with a meta-analysis of 511 patients proposing a correlation between detection of CD44v6 and worse overall survival (Fan et al., 2012; Saito et al., 2013) , the analysis of a large cohort of primary and metastatic CRCs showed a significant negative correlation between CD44v6 expression and survival probability of CRC patients ( Figures 7A-7D ). This correlation was not detectable in patients with stage I and II, most likely because a higher number of patients and a longer followup would be required to detect differences in low-stage tumors (Figure S7A ). Of note, multivariate analysis indicated that CD44v6 is an independent negative prognostic factor in both cohorts of patients ( Figure S7B ). Given that HGF, OPN, and SDF-1 induce the expression of CD44v6 in immature CRC cells, we investigated the possible correlation of these cytokines with the presence of CD44v6 in tumor specimens from CRC patients. The analysis of ten patients showed that HGF, OPN, and SDF-1 are present at higher levels in tumors with increased number of CD44v6 + cells as compared with tumors with fewer or no CD44v6 + cells ( Figure S7C ), suggesting that the three cytokines contribute to increase the number of CD44v6 + cells in tumors of CRC patients.
DISCUSSION
Here, we demonstrated that CR-CSCs express CD44v6, which is a functional marker able to confer the ability to migrate at distant sites and develop CRC metastasis, as confirmed by the significant inverse correlation between patient survival and CD44v6 expression. Several groups have identified tumorigenic populations with stem-like features in CRC (Barker et al., 2007; Dalerba et al., 2007; Huang et al., 2009; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Todaro et al., 2007; Vermeulen et al., 2008 Vermeulen et al., , 2010 . These cells are able to promote tumor growth and are regarded as an ideal cell target to obtain effective therapies. However, the growth of primary tumors is usually not life-threatening, unlike the occurrence of metastatic lesions (Valastyan and Weinberg, 2011) . Because MET is widely expressed in CRC (Takeuchi et al., 2003) , the concomitant expression of CD44v6 and MET in all CR-CSCs empowers these cells to form metastasis and severely affect patient prognosis (Minoo et al., 2010; Peng et al., 2008) . EMT is exploited by cancer cells to increase self-renewal and migration through a process that favors the emergence of CSCs (Mani et al., 2008) . We show that CD44v6 + CRC cells display b-catenin activation and EMT traits coupled with a considerable migratory activity, which explains the metastatic features of immunocompromised mice treated with these cells. Our data reveal that the EMT and metastatic potential of CR-CSCs is increased by microenvironmental signals promoting the expression of CD44v6. HGF, SDF-1, and OPN are potent inducers of CD44v6 and provide metastatic activity to tumorigenic cells. Targeting MET or CD44v6 completely prevented the invasive capability of the tumorigenic CRC cells, indicating that the metastatic potential depends on signaling generated by HGF via CD44v6 and MET. These receptors cooperate to activate the PI3K/AKT pathway, which promotes migration and survival signaling in CR-CSCs. Activation of Wnt signaling plays a key role in maintaining the stem cell pool in the gut and promoting self-renewal of CR-CSCs (de Lau et al., 2011; Leedham et al., 2013; Ootani et al., 2009; van Es et al., 2012) . Cytokines released in the microenvironment contribute significantly to maintain the undifferentiated status and clonogenic activity of the tumorigenic cells (Bissell and Labarge, 2005; Medema and Vermeulen, 2011; Vermeulen et al., 2010) . Our data indicate that this property is not confined to HGF (Vermeulen et al., 2010) , but it is shared by OPN and SDF-1, which enhance b-catenin activation in CRCSCs. A similar effect may be mediated by TGF-b, which is produced by both CAFs and CD44v6 + cells. Whereas CAFs seem to play a key role in the induction of CD44v6, it is likely that autocrine production of OPN and TGF-b may contribute to promote the metastatic activity of CD44v6 + cells. The inability of all these cytokines to induce the expression of CD44v6 on more-differentiated CRC cells may be related to the low activation of b-catenin observed in these cells, despite the presence of genomic alterations that should provide a constitutive activation of the Wnt pathway. Thus, CD44v6 expression appears as part of a more complex system that confers self-renewal and metastatic properties to CR-CSCs. Targeting CD44v6 expression prevented metastasis formation without affecting the growth of primary tumors. Likewise, delivery of CD44v6 in negative cells restores migration and in vivo colonization, without providing self-renewal properties to target cells. We recently demonstrated that BMP4 counteracts Wnt activity in CR-CSCs and promotes their differentiation via upregulation of PTEN and inhibition of PI3K (Lombardo et al., 2011) , which maintain the undifferentiated status of the tumorigenic population (Vermeulen et al., 2008) . CD44v6 + cells show enhanced activation of the PI3K/AKT pathway, which is triggered by ligand binding and by the epigenetic silencing of PTEN that characterized CR-CSCs (Lombardo et al., 2011; Ricci-Vitiani et al., 2010) . PI3K promotes the expression of CD44v6 in CRC progenitors, whereas its inhibition impairs migration and survival of CD44v6 + CRC cells, which are significantly more sensitive to PI3K inhibition than the CD44v6 À counterpart. Because clinical trials with available drugs targeting PI3K or HGF pathways have not been designed in the adjuvant setting, these findings may have considerable therapeutic implications (Ghiso and Giordano, 2013; Rodon et al., 2013) . Although some CD44v6 À cells could be tumorigenic and develop small tumors, most tumorigenic activity seems to be confined in the CD44v6 + population, which contains virtually all the cells with high b-catenin activation. Because there is a significant overlap between tumorigenic and metastagenic cells, it is likely that the relative density of CSCs in CRC directly correlates with the metastatic propensity of tumor lesions. In this context, CD44v6 appears as a key functional biomarker critically involved in the main features of cancer progression.
EXPERIMENTAL PROCEDURES
Five-week-old nonobese diabetic/severe combined immunodeficiency mice from Charles River Laboratories were maintained in accordance to the institutional guidelines of the University of Palermo Animal Care Committee.
Tissue Collection an Isolation and Culture of Cancer Cells Colorectal cancer tissues were obtained at the time of resection from 36 patients (age range 52-78 years) and liver metastasis from 18 matched patients, in accordance with the ethical standards of the Institutional Committee on Human Experimentation (see Table S1 ). Normal colon mucosa was obtained from the histologically uninvolved resection.
Sphere purification and sphere-derived adherent cultures (SDACs) were obtained as previously described (Lombardo et al., 2011; Todaro et al., 2007) .
Primary fibroblasts were isolated from colorectal cancer tissues, cultured in presence of 10% FBS Dulbecco's modified Eagle's medium in adherent conditions, and indicated as CAFs. Murine colon carcinoma cells (colon-26) were cultured in medium supplemented with 2 mM L-glutamine and 10% FBS in adherent conditions (CLS Cell Lines Service). were assessed on cells treated with HGF (100 ng/ml), OPN (1 mg/ml), SDF (100 ng/ml), 10% FBS, CAF-CM, transforming growth factor-beta1 (recombinant human TGF-b1; 4 ng/ml; Peprotech), and BKM120. Cells were also preor posttreated with BMP2 or BMP4 (100 ng/ml; R&D Systems) up to 6 days.
Flow Cytometry and Magnetic Sorting
Immunofluorescence/Immunohistochemistry
Cells were fixed and permeabilized as previously reported and exposed overnight at 4 C to antibodies against CD133 (AC133; mouse IgG 1 ; Miltenyi Biotec), MET (c-28; rabbit IgG; Santa Cruz Biotechnology), CD44v6 (2F10; mouse IgG1; R&D Systems), b-catenin (H102; rabbit IgG; Santa Cruz Biotechnology), or isotype-matched controls. Then, cells were labeled with secondary antibodies (Invitrogen). Nuclei counterstaining was performed using Toto-3 iodide. Tissue microarrays (TMAs) slides were exposed to specific antibodies against CD44v6, examined microscopically by three independent observers blinded to clinicopathological information, and stratified according to the CD44v6 expression.
Invasion Assay
Cells (1.5 3 10 3 ), untreated and treated with hepatocyte growth factor (recombinant human HGF; 100 ng/ml; Peprotech), osteopontin (OPN; 1 mg/ml; Sigma), stromal-cell-derived factor-1a (recombinant human SDF-1a; 100 ng/ml; Peprotech), CAF-CM, neutralizing antibody against CD44v6 (15 mg/ml; 2F10; mouse IgG 1 ; R&D Systems), isotype-matched control (15 mg/ml; human in the transwell lower part. Antibodies against HGF (10 mg/ml; 24612; mouse IgG 1 ; R&D Systems) and OPN (5 mg/ml; AF1433; goat IgG; R&D Systems) were mixed with conditioned medium and placed in the lower part of transwell. AMD3100 (50 mM; Sigma-Aldrich) was added to sphere cells for 90 min and replaced every 6 hr up to 72 hr in the upper part of the transwell. Migration was observed and counted microscopically up to 72 hr.
Clonogenic Assay
Cells were plated in presence of stem cell medium, CAF-CM or Wnt3a, replaced every 5 days, on ultra-low-adhesion 96-well plates at a concentration of a single cell per well. Wells containing either none or more than one cell were excluded for the analysis. transduced with LUC/GFP were injected into the spleen of BALB/c-mice.
Animals and Orthotopic Tumor Model
Cytokines Quantification
Quantification for HGF, OPN, SDF-1, and TGFÀb production was assessed by using multiplex Bio-Plex Pro Assays (Bio-Rad; Human Cancer Biomarker Real-Time PCR Quantitative real-time PCR analysis was performed in a master mix containing the following primer sets: Hs00300159_m1 (HGF), Hs00959010_m1 (OPN), Hs00998133_m1 (TGF-b1), Hs00171022_m1 (SDF-1), and Hu-GAPDH (Applied Biosystems). Data processing and statistical analysis were performed using the ABI PRISM SDS software v2.1 (Applied Biosystems). The RT 2 Profiler PCR array was assessed for genes related to Wnt targets, EMT, and tumor metastasis (TM) (PAHS-243ZR-12, PAHS-090ZR, PAHS-028ZR-12; SuperArray Bioscience). Cycle threshold values were calculated for all the genes present on the array and normalized using the average of five housekeeping genes (ACTB, B2M, HPRT1, RPLP0, and GAPDH). RT 2
Profiler PCR array data analysis was represented by clustergrams based on Pearson's correlation of 2^(DCt).
Statistical Analysis
Data were expressed as mean ± SD. Statistical significance was determined by ANOVA (one-way or two-way) with Bonferroni posttest. For TMA analysis, associations between categorical variables were tested by the Pearson Chi-Square test, Fisher Exact tests, or Chi square for trend, when appropriate. The receiver-operating characteristic curve analysis was used in order to find possible optimal cutoffs of the CD44v6 capable of splitting patients into groups with different outcomes probabilities. Kaplan-Meier method was used to estimate survival curves, whereas differences between subgroups were assessed by the log rank test. All significance was defined at the p < 0.05 level.
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